News stories about Esperion Therapeutics (NASDAQ:ESPR) have trended somewhat positive this week, Accern Sentiment Analysis reports. The research firm ranks the sentiment of news coverage by analyzing more than twenty million blog and news sources in real time. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Esperion Therapeutics earned a daily sentiment score of 0.23 on Accern’s scale. Accern also assigned news stories about the biopharmaceutical company an impact score of 45.4670468078265 out of 100, indicating that recent news coverage is somewhat unlikely to have an effect on the stock’s share price in the next several days.
These are some of the media headlines that may have effected Accern Sentiment Analysis’s scoring:
- Esperion Therapeutics (ESPR) Upgraded to Strong-Buy at BidaskClub (americanbankingnews.com)
- Notable Friday Option Activity: BLK, ESPR, CZR – Nasdaq (nasdaq.com)
- Analysts recommended an average rating score of 1.90 for Esperion Therapeutics, Inc. (ESPR) – Wall Street Morning (wallstreetmorning.com)
- Biotech with Non-Statin Cholesterol Lowering Drug Poised for Significant Catalysts in 2018 (investorideas.com)
- Investor Watch: Target Price Focus on Shares of Esperion Therapeutics, Inc. (NASDAQ:ESPR) – Clawson News (clawsonnews.com)
Shares of Esperion Therapeutics (ESPR) opened at $73.26 on Friday. The firm has a market cap of $1,831.48, a price-to-earnings ratio of -10.66 and a beta of 2.73. Esperion Therapeutics has a one year low of $10.71 and a one year high of $74.95.
Several research firms have weighed in on ESPR. Northland Securities reissued a “buy” rating and issued a $72.00 price target on shares of Esperion Therapeutics in a research note on Wednesday, October 4th. Stifel Nicolaus reissued a “buy” rating and issued a $70.00 price target on shares of Esperion Therapeutics in a research note on Wednesday, October 4th. Chardan Capital reissued a “neutral” rating and issued a $75.00 price target (up from $20.00) on shares of Esperion Therapeutics in a research note on Tuesday, December 5th. BidaskClub downgraded shares of Esperion Therapeutics from a “buy” rating to a “hold” rating in a research note on Thursday, December 7th. Finally, Needham & Company LLC raised shares of Esperion Therapeutics from a “buy” rating to a “strong-buy” rating and boosted their price target for the stock from $72.00 to $81.00 in a research note on Thursday, December 14th. Six equities research analysts have rated the stock with a hold rating, eight have given a buy rating and two have issued a strong buy rating to the stock. The stock currently has an average rating of “Buy” and an average price target of $62.08.
In other news, Director Nicole Vitullo sold 9,326 shares of the company’s stock in a transaction dated Wednesday, December 6th. The shares were sold at an average price of $53.85, for a total transaction of $502,205.10. Following the completion of the transaction, the director now directly owns 2,472 shares of the company’s stock, valued at $133,117.20. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Corporate insiders own 32.50% of the company’s stock.
COPYRIGHT VIOLATION WARNING: “Somewhat Favorable Media Coverage Somewhat Unlikely to Affect Esperion Therapeutics (ESPR) Share Price” was originally posted by Markets Daily and is the property of of Markets Daily. If you are reading this report on another site, it was illegally stolen and republished in violation of United States & international copyright and trademark legislation. The original version of this report can be viewed at https://www.themarketsdaily.com/2018/01/14/somewhat-favorable-media-coverage-somewhat-unlikely-to-affect-esperion-therapeutics-espr-share-price.html.
Esperion Therapeutics Company Profile
Esperion Therapeutics, Inc is a lipid management company. The Company is a late-stage pharmaceutical company focused on developing and commercializing once-daily, oral therapies for the treatment of patients with elevated low-density lipoprotein cholesterol (LDL-C). With a targeted mechanism of action, bempedoic acid, the Company’s lead product candidate, is an orally available, once-daily adenosine triphosphate (ATP)-citrate lyase (ACL) inhibitor that reduces cholesterol biosynthesis and lowers elevated levels of LDL-C by up-regulating the LDL receptor, but with reduced potential for muscle-related side effects.
Receive News & Ratings for Esperion Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Esperion Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.